This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Summary: In this issue, Kamata-Sakurai and colleagues describe an agonist antibody to CD137 (4-1BB) that takes on an active conformation in environments with high ATP concentrations, characteristic of tumors. This represents a novel advancement in developing immunotherapies that can be administered systemically, but act locally to induce antitumor immune responses without the usual attendant toxicities.
See related article by Kamata-Sakurai et al., p. 158.
Footnotes
Cancer Discov 2021;11:20–2
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
Conditional Cancer Immunotherapy as a Safer Way to Step on the Gas
Jump to section
Advertisement